佳惟达生物完成数千万元A轮融资，助力重组胶原蛋白原料产品商业化放量

Core Viewpoint - Jiaweida (Hangzhou) Biotechnology Co., Ltd. has completed several million yuan in Series A financing, aiming to accelerate the commercialization of its recombinant collagen products [1][2]. Group 1: Company Overview - Jiaweida Biotechnology was established in 2022 and focuses on an efficacy and demand-driven synthetic biology manufacturing platform for medical beauty and cosmetic applications [1]. - The company has built a synthetic biology platform that meets pharmaceutical quality standards and has established cooperation intentions with the cosmetics industry [1]. Group 2: Product Development - The company has made significant progress in its innovative pipeline, including special recombinant small molecule collagen, functional peptides, recombinant antimicrobial peptides, and recombinant human full-length triple-helix collagen raw materials [2]. - The recombinant small molecule collagen product has completed pilot testing, with expression levels at the industry's upper tier [1]. - The recombinant human full-length collagen product has completed molecular design and cell line construction, with independent third-party testing confirming typical circular dichroism characteristics [1].